Journal of Dermatologic Research And Therapy

Honglin Wang, Executive Vice President of the Institute for Clinical Research, and Director and PI of Precision Research Center for Refectory Diseases, Shanghai General Hospital, Shanghai, Shanghai
Editorial Board

Honglin Wang Ph.D. (Universität Ulm)

Executive Vice President of the Institute for Clinical Research, and Director and PI of Precision Research Center for Refectory Diseases, Shanghai General Hospital, Shanghai, Shanghai · China

Editorial leadership for Journal of Dermatologic Research And Therapy ISSN 2471-2175

Research interests

  • Dermatology
  • Immunology
  • Psoriasis
  • Neuroimmunology
  • Stem Cells
  • T Cells

Biography

  • Dr. Honglin Wang, is Professor of Special Appointment (Eastern Scholar) and Principle Investigator at Shanghai Jiao Tong University School of Medicine. 
  • From 2002 to 2006, Dr. Wang conducted his doctoral study in skin immunology and molecular medicine at Ulm University, Germany. 
  • In 2007, he received Outstanding Doctoral Dissertation Award (Summa Cum Laude) and Merck Serono Prize. 
  • After obtaining his Ph.D. degree, Dr. Wang continued working as a postdoctoral research associate at University of Ulm School of Medicine. 
  • Between 2002 and 2009, he participated in European collaborative research programs with Lund University at Sweden. 
  • Since 2009, Dr. Wang returned to China and established Laboratory of Skin Immunology at Shanghai Institute of Immunology, Institute of Medicine Sciences, Shanghai Jiao Tong University School of Medicine. 
  • Dr. Wang’s lab is focusing on skin stem cells, epigenetic regulation in T cell function and inflammatory skin diseases.

Considering JDRT for your work?

This journal is guided by Honglin Wang (Executive Vice President of the Institute for Clinical Research, and Director and PI of Precision Research Center for Refectory Diseases, Shanghai General Hospital, Shanghai, Shanghai) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.

Start your submission

Menu